2022 to 2023 Saw No Change in U.S. Infant Mortality Rate
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 14, 2024 -- The U.S. infant mortality rate did not change from 2022 to 2023 and was 5.61 per 1,000 live births in 2023, according to the Nov. 14 National Vital Statistics Reports, a publication from the National Center for Health Statistics.
Danielle M. Ely, Ph.D., and Anne K. Driscoll, Ph.D., from the National Center for Health Statistics in Hyattsville, Maryland, present provisional 2023 data on infant mortality rates using linked birth/infant death files. Comparisons were made between provisional 2023 and final 2022 data.
The researchers found that the U.S. provisional infant mortality rate in 2023 was 5.61 infant deaths per 1,000 live births, which was unchanged from the 2022 rate. Changes in the neonatal mortality rate (from 3.59 to 3.65) and postneonatal mortality rate (from 2.02 to 1.96) from 2022 to 2023 were not significant. By most of the characteristics examined, changes in infant mortality rates were not significant: maternal race and Hispanic origin, maternal age, gestational age, sex, or the 10 leading causes of infant death. Nevada and Washington had increases in infant mortality rates, while declines were seen in New Mexico and West Virginia.
"This report provides more timely information than reports based on final linked birth/infant death file data and provides details by maternal and infant characteristics, such as maternal race and Hispanic origin and gestational age, which are unavailable in provisional mortality data releases," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-16 00:00
Read more
- Antibiotics or Surgery: What's Best for Child Appendicitis?
- Electronic Sepsis Screening Reduces 90-Day In-Hospital Mortality
- Antiobesity Medications Tied to Decreased Alcohol Use
- Irregular Sleep Linked to Increased Risk for Major Adverse Cardiovascular Events
- Older Adults With Migraine Experienced Higher Depression Risk During Pandemic
- FDA Approves Bimzelx for Hidradenitis Suppurativa
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions